Drug intelligence / Profile preview

EB-103

Development stage: Preclinical
Lead developer: Elastin Biosciences
Modality: Small Molecules

Overview

EB-103 is a small molecule drug candidate developed by Elastin Biosciences, currently in the IND-enabling phase for the treatment of cardiovascular diseases. Developed using a proprietary cheminformatics platform, EB-103 is designed to restore tissue structural integrity by boosting the production of elastin and strengthening the elastin-based extracellular matrix. This approach aims to address conditions characterized by elastin degradation, particularly within the cardiovascular system. As of early 2024, the candidate has completed proof-of-concept studies and is undergoing IND-enabling activities to support future clinical trials.

Targets

ELN (Elastin)

Beyond the preview

Go deeper on EB-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-103.

Explore the full profile